Rise in Testing of Unregulated Peptides in UK Amid Weight-Loss and Wellness Demand

Laboratories testing unregulated peptides have seen a sharp increase in submissions from the UK, driven by demand for injectable substances promoted for weight loss and wellness. Finnrick, a Texas-based lab, processes around 60,000 samples annually, including approximately 2,000 orders from the UK since 2024.

Janoshik Analytical in the Czech Republic handles 5,000 samples monthly, with the UK ranking third globally in testing volume alongside Canada. Peptides are short chains of amino acids, occurring naturally in the body as hormones like insulin and synthetically produced for various uses.

They form the basis of prescription drugs such as Wegovy, which contains semaglutide mimicking the GLP-1 hormone, and Mounjaro, which uses tirzepatide. Unregulated versions, including bootleg copies of these drugs and experimental compounds like retatrutide, are sold online for research purposes only but injected by users.

Quality issues persist in these products. Finnrick analysis shows about one-third of thousands of tested peptides fail checks for identity, purity below 98%, or incorrect quantity. The lab purchases samples through consumer channels and accepts public submissions since June 2023, flagging vendor-direct products on its site.

The peptide-testing industry expanded rapidly over the past three to four years, coinciding with the popularity of GLP-1 drugs. Peter Magic, chemist at Janoshik Analytical, attributed the surge to semaglutide, followed by tirzepatide and retatrutide, which remains in clinical trials and unapproved in the UK, making its sale illegal.

Vendors exploit a legal grey area by labeling products for research, avoiding medicine classification and oversight. Profit margins are high, with vials bought for $15 in China and resold for 10 times that amount, attracting unregulated suppliers. The UK market ties with performance-enhancing drug channels, sharing factories and distribution.

TikTok hosts extensive promotion, with analysis of over 5,000 videos showing 64% from US accounts and 16% from UK creators. Users claim benefits like injury healing, focus enhancement, and wrinkle reduction.

warn of risks including mislabeled products, overdosing, underdosing, and lack of long-term clinical data. Dr. Luke Turnock, senior lecturer in criminology at the University of Lincoln, noted potential harms such as increased cancer risk or organ damage not immediately apparent.

“— Dr. Luke Turnock, University of Lincoln (The Guardian)”

User reports on platforms like TikTok describe emotional side effects from retatrutide and similar drugs. Accounts mention reduced lust, severe anhedonia, and feeling unbothered by most things, with videos questioning if these substances cause falling out of love.

Medical researchers are investigating whether these drugs act as reward dampeners in the brain's mesolimbic system, affecting not only appetite but also joy and motivation. Reports of emotional flatness and depressive symptoms have emerged for approved GLP-1 drugs like Mounjaro.

Paul Kenny, neuroscientist at Icahn School of Medicine at Mount Sinai, described widespread GLP-1 use as a large-scale experiment revealing behavioral impacts beyond weight loss.

Amira Guirguis, chief scientist at the Royal Pharmaceutical Society, emphasized the need for oversight, traceability, and quality assurance for substances with biological effects. Retail-style websites selling peptides bypass controlled systems, raising questions about safety when injected.

Retatrutide targets three appetite-related hormones and remains experimental, yet users source it illegally online. While prescription peptides undergo rigorous testing, unregulated ones lack such validation, contributing to the testing boom as consumers seek verification.